Major companies committed to joining Medicare drug price negotiations; Boehringer Ingelheim introduced a low-cost version of its adalimumab biosimilar; schools begin to stock naloxone amid rising opioid deaths among young people.
Pharmaceutical companies including Johnson & Johnson, Merck, and Bristol Myers Squibb have agreed to participate in Medicare drug price negotiations with the federal government, according to the Biden administration, NBC News reported. The negotiations are expected to begin next year, with the negotiated prices taking effect in 2026. The drug companies are the makers of the first 10 prescription drugs subject to price negotiations, including medications for conditions like diabetes and rheumatoid arthritis. Lawsuits from some of the drug companies are still ongoing.
Boehringer Ingelheim has released an unbranded version of its biosimilar for AbbVie's Humira (adalimumab) in the United States with a list price at an 81% discount to the reference drug, according to Reuters. This move comes after the launch of a branded biosimilar, Cyltezo (adalimumab-adbm), priced at a 5% discount to Humira's list price. Boehringer Ingelheim's biosimilars for Humira are designated as interchangeable by the FDA, allowing them to be substituted for the original without prescriber consultation. With 8 adalimumab biosimilars entering the US market this year, competition among manufacturers is growing, and several are seeking interchangeability status with the FDA.
In Colorado, some school districts are facing a decision about whether to stock naloxone, a medication that rapidly reverses opioid overdoses, in their schools, according to KFF Health News. While more districts have enrolled in the state's program to obtain naloxone at a reduced cost or for free since passage of a state law in 2019, only about a third of Colorado districts had done so at the beginning of the current school year. The reluctance to stock naloxone is often due to concerns about stigma, providing a medical service, resupplying naloxone, and fears of the school being perceived as having a drug problem. However, health officials recommend its availability as opioid overdose deaths among young people continue to rise.
Enhancing Outpatient Hemophilia Care May Improve Health Outcomes and Costs
May 18th 2024Prospective data from patients attending a rural practice in West Virginia between 2016 and 2023 show that a quality improvement program that followed guideline recommendations and was tailored to specific patient needs reduced preventable bleeds and lowered costs.
Read More
Frameworks for Advancing Health Equity: Urban Health Outreach
May 9th 2024In the series debut episode of "Frameworks for Advancing Health Equity," Mary Sligh, CRNP, and Chelsea Chappars, of Allegheny Health Network, explain how the Urban Health Outreach program aims to improve health equity for individuals experiencing homelessness.
Listen